Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy

Gut and Liver

Volumn 4, Issue 3, 2010, Pages 423-427

  Yang, Mi Yean ^a   Jeong, Soung Won ^a   Kim, Dong Kyun ^a   Kim, Sang Gyune ^a   Jang, Jae Young ^a   Kim, Young Seok ^a   Lee, Joon Seong ^a   Kim, Boo Sung ^a   Kim, Jung Hoon ^a   Kim, Yong Jae ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Portal vein thrombosis; Sorafenib

Indexed keywords

CISPLATIN; FLUOROURACIL; LAMIVUDINE; SORAFENIB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIPLE CYCLE TREATMENT; PORTAL VEIN THROMBOSIS; REVASCULARIZATION;

EID: 77957554139     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2010.4.3.423     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442. (Pubitemid 36152543)
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - An updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-1547. (Pubitemid 43727460)
6. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12:7561-7567. (Pubitemid 46040565)
7. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928.
8. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100:1995-2004. (Pubitemid 43919392)
9. Asahara T, Itamoto T, Katayama K, et al. Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculatures. Hepatogastroenterology 1999;46:1862-1869.
10. Tanaka A, Morimoto T, Yamaoka Y. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996;43:637-643. (Pubitemid 26190123)
11. Yamaoka Y, Kumada K, Ino K, et al. Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg 1992;16:1172-1177.
12. Furuse J, Iwasaki M, Yoshino M, et al. Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 1997;204:787-790.
13. Yen FS, Wu JC, Kuo BI, Chiang JH, Chen TZ, Lee SD. Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. J Gastroenterol Hepatol 1995;10:237-240.
14. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1890-1896.
15. Iwamiya T, Sawada S, Ohta Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994;33 Suppl:S134-S138.
16. Chen SC, Lian SL, Chang WY. The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33 Suppl:S124-S127.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
18. Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349.
19. Plastaras JP, Kim SH, Liu YY, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007;67:9443-9454.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
21. Novi M, Lauritano EC, Piscaglia AC, et al. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol 2009;104:1852-1854.
22. Li Q, Xu B, Fu L, Hao XS. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res 2006;25:403-409.